Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,456.20 | 90.50 | 1.08% |
CAC 40 | 7,770.48 | 176.61 | 2.33% |
DAX 40 | 23,086.65 | 589.67 | 2.62% |
Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
FTSE 100 | 8,596.35 | 99.55 | 1.17% |
HKSE | 22,504.68 | 385.27 | 1.74% |
NASDAQ | 17,977.73 | 266.99 | 1.51% |
Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
NZX 50 Index | 12,327.89 | 179.29 | 1.48% |
S&P 500 | 5,686.67 | 82.53 | 1.47% |
S&P/ASX 200 | 8,238.00 | 92.40 | 1.13% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |